600 likes | 2.06k Views
Bone Graft Function. Structural support of articular fractureTibial plateau fracturePrevent post-op collapseVoid filler to prevent fractureCyst excisionImproved healing of fracture and nonunionsSpeed healingFewer nonunions. Mechanisms of Bone Growth. OsteoconductionProvides matrix for bone growthOsteoinductionGrowth factors encourage mesenchymal cells to differentiate into osteoblastic lineagesOsteogenesisTransplanted osteoblasts and periosteal cells directly produce bone.
E N D
1. Bone Grafting and Bone Graft Substitutes
2. Bone Graft Function Structural support of articular fracture
Tibial plateau fracture
Prevent post-op collapse
Void filler to prevent fracture
Cyst excision
Improved healing of fracture and nonunions
Speed healing
Fewer nonunions Bone grafts, and bone graft substitutes, are used primarily for three main purposes. One, to provide structural support, such as after elevation of a depressed tibial plateau fracture. Second, to fill a void, such as after excision of a bone cyst in an area that does not demand any structural support. Third, to improve fracture healing. Either by speeding healing or increasing the successful union rate.Bone grafts, and bone graft substitutes, are used primarily for three main purposes. One, to provide structural support, such as after elevation of a depressed tibial plateau fracture. Second, to fill a void, such as after excision of a bone cyst in an area that does not demand any structural support. Third, to improve fracture healing. Either by speeding healing or increasing the successful union rate.
3. Mechanisms of Bone Growth Osteoconduction
Provides matrix for bone growth
Osteoinduction
Growth factors encourage mesenchymal cells to differentiate into osteoblastic lineages
Osteogenesis
Transplanted osteoblasts and periosteal cells directly produce bone
4. Types of Bone Grafts Autograft
Allograft
Bone graft substitutes
Most have osteoconductive properties
Osteoinductive agents
rhBMP-2 (Infuse) and rhBMP-7 (OP-1)
5. Autogenous Bone Graft “Gold standard”
Standard by which other materials are judged
May provide osteoconduction, osteoinduction and osteogenesis
Drawbacks
Limited supply
Donor site morbidity
6. Autogenous Bone Grafts Cancellous
Cortical
Free vascular transfers
Bone marrow aspirate
The most common form of autogenous bone graft is cancellous bone, usually harvested from either anterior or posterior iliac crests, but which also may be harvested locally such as in the proximal tibia or distal radius. Cortical bone strips may be harvested from the inner table of the pelvis. Occasionally a vascularized bone graft may be used, such ass a free fibular transfer. Another option for obtaining osteogenic cells is by bone marrow aspirate.The most common form of autogenous bone graft is cancellous bone, usually harvested from either anterior or posterior iliac crests, but which also may be harvested locally such as in the proximal tibia or distal radius. Cortical bone strips may be harvested from the inner table of the pelvis. Occasionally a vascularized bone graft may be used, such ass a free fibular transfer. Another option for obtaining osteogenic cells is by bone marrow aspirate.
7. Cancellous Bone Grafts Three dimensional scaffold (osteoconductive)
Osteocytes and stem cells (osteogenic)
A small quantity of growth factors (osteoinductive)
Little initial structural support
Can gain support quickly as bone is formed
8. Cortical Bone Grafts Less biologically active than cancellous bone
Less porous, less surface area, less cellular matrix
Prologed time to revascularizarion
Provides more structural support
Can be used to span defects
Vascularized cortical grafts
Better structural support due to earlier incorporation
Also osteogenic, osteoinductive
Transported periosteum
9. Bone Marrow Aspirate Osteogenic
Mesenchymal stem cells (osteoprogenitor cells) exist in a 1:50,000 ratio to nucleated cells in marrow aspirate
Numbers decrease with advancing age
Can be used in combination with an osteoconductive matrix
10. Autograft Harvest Cancellous
Iliac crest (most common)
Anterior- taken from gluteus medius pillar
Posterior- taken from posterior ilium near SI joint
Metaphyseal bone
May offer local source for graft harvest
Greater trochanter, distal femur, proximal or distal tibia, calcaneus, olecranon, distal radius, proximal humerus
11. Autograft Harvest Cancellous harvest technique
Cortical window made with osteotomes
Cancellous bone harvested with gouge or currette
Can be done with trephine instrument
Circular drills for dowel harvest
Commercially available trephines or “harvesters”
Can be a percutaneus procedure
12. Autograft Harvest Cortical
Fibula common donor
Avoid distal fibula to protect ankle function
Preserve head to keep LCL, hamstrings intact
Iliac crest
Cortical or tricortical pieces can be harvested in shape to fill defect
13. Bone Allografts Cancellous or cortical
Plentiful supply
Limited infection risk (varies based on processing method)
Provide osteoconductive scaffold
May provide structural support
14. Bone Allografts Available in various forms
Processing methods may vary between companies / agencies
Fresh
Fresh Frozen
Freeze Dried
15. Bone Allografts Fresh
Highly antigenic
Limited time to test for immunogenicity or diseases
Use limited to joint replacement using shape matched osteochondral allografts
16. Bone Allografts Fresh frozen
Less antigenic
Time to test for diseases
Strictly regulated by FDA
Preserves biomechanical properties
Good for structural grafts
17. Bone Allografts Freeze-dried
Even less antigenic
Time to test for diseases
Strictly regulated by FDA
Can be stored at room temperature up to 5 years
Mechanical properties degrade
18. Graft Incorporation Hematoma formation
Release of cytokines and growth factors
19. Graft Incorporation Hematoma formation
Release of cytokines and growth factors
Inflammation
Development of fibrovascular tissue
20. Graft Incorporation Hematoma formation
Release of cytokines and growth factors
Inflammation
Development of fibrovascular tissue
Vascular ingrowth
Often extending Haversian canals
21. Graft Incorporation Hematoma formation
Release of cytokines and growth factors
Inflammation
Development of fibrovascular tissue
Vascular ingrowth
Often extending Haversian canals
Focal osteoclastic resorption of graft
22. Graft Incorporation Hematoma formation
Release of cytokines and growth factors
Inflammation
Development of fibrovascular tissue
Vascular ingrowth
Often extending Haversian canals
Focal osteoclastic resorption of graft
Intramembranous and/or endochondral bone formation on graft surfaces
23. Graft Incorporation Cancellous bone interface between graft and host bone
24. Graft Incorporation Cortical allograft strut graft placed next to cortex of host
After 4 years of incorporation
25. Partial incorporation of hydroxyapatite bone graft substitute\
Biopsy of material obtained 1 year post-op Bone Graft Substitute Incorporation
26. Bone Graft Substitutes Need for bone graft alternatives has lead to development of numerous bone graft substitutes
Avoid morbidity of autogenous bone graft harvest
Mechanical properties vary
Most offer osteoconductive properties
Some provide osteoinductive properties
27. Bone Graft SubstitutesPotential Roles Extender for autogenous bone graft
Large defects
Multiple level spinal fusion
Enhancer
To improve success of autogenous bone graft
Substitute
To replace autogenous bone graft
28. Bone Graft Substitutes Calcium phosphate
Calcium sulfate
Collagen based matrices
Demineralized bone matrix
Hydroxyapatite
Tricalcium phosphate
Osteoinductive proteins
29. Bone Graft Substitutes Resorption rates vary widely
Dependant on composition
Calcium sulfate - very rapid
Hydroxyapatite (HA) – very, very slow
Some products may be combined to optimize resorption rate
Also dependant on porosity, geometry
30. Bone Graft Substitutes Mechanical properties vary widely
Dependant on composition
Calcium phosphate cement has highest compressive strength
Cancellous bone compressive strength is relatively low
Many substitutes have compressive strengths similar to cancellous bone
All designed to be used with internal fixation
31. Calcium Phosphate Injectable pastes of calcium and phospate
Norian SRS (Synthes/Stratec)
Alpha BSM (Etex/Depuy)
Callos Bone Void Filler (Skeletal Kinetics) Calcium phosphate products are an injectable paste of calcium and phosphate.
Norian SRS was the first such product available and is marketed by Synthes / Stratec.
Two other calcium phosphate type products are also available in the U.S.Calcium phosphate products are an injectable paste of calcium and phosphate.
Norian SRS was the first such product available and is marketed by Synthes / Stratec.
Two other calcium phosphate type products are also available in the U.S.
32. Calcium Phosphate
33. Calcium Sulfate Medical grade calcium sulfate is an osteoconductive void filler. It has low compressive strength so doesn’t offer structural support. Another disadvantage of the product is that it resorbs rather rapidly, perhaps more rapidly then it can be replaced by new bone. One way it which it may be used is an extender for autogenous bone graft.Medical grade calcium sulfate is an osteoconductive void filler. It has low compressive strength so doesn’t offer structural support. Another disadvantage of the product is that it resorbs rather rapidly, perhaps more rapidly then it can be replaced by new bone. One way it which it may be used is an extender for autogenous bone graft.
34. Pellets
Pellet injectors
Bead kits
Allows addition of antibiotics
Injectable
May be used to augment screw purchase Calcium Sulfate Calcium sulfate products are available both as pellets, bead kits, and injectable preparations. The pellets can be poured into position, but some companies also provide an injector apparatus. The bead kits allow the addition of antibiotics if desired.Calcium sulfate products are available both as pellets, bead kits, and injectable preparations. The pellets can be poured into position, but some companies also provide an injector apparatus. The bead kits allow the addition of antibiotics if desired.
35. Collagen Based Matrices Highly purified Type 1 bovine dermal fibrillar collagen
Bone marrow is added to provide bone forming cells
Collagraft (Zimmer)
Collagen / HA / Tricalcium phosphate
Healos (Depuy)
Collagen / HA
36. Demineralized Bone Matrix Prepared from cadaveric human bone
Acid extraction of bone leaving
Collagen
Noncollagenous proteins
Bone growth factors
BMP quantity extremely low and variable
Sterilized which may decrease the availability of BMP
37. Available from multiple vendors in multiple preparations
Gel
Putty
Strip
Combination products with cancellous bone and other bone graft substitute products Demineralized Bone Matrix
38. Growth factor activity varies between tissue banks and between batches
While they may offer some osteoinductive potential because of available growth factors, they mainly act as an osteoconductive agents
Demineralized Bone Matrix
39. Hydroxyapatite Produced from marine coral exoskeletons that are hydrothermically converted to hydroxyapatite, the natural mineral composition of bone
Interconnected porous structure closely resembles the porosity of human cancellous bone
40. Hydroxyapatite Marketed as ProOsteon by Interpore Cross
Available in various size blocks & granules
ProOsteon 500
Very slow resorption
ProOsteon 500 R
Only a thin layer of HA
Faster resorption
41. Tricalcium Phosphate Wet compressive strength slightly less than cancellous bone
Available as blocks, wedges, and granules
Numerous tradenames
Vitoss (Orthovita)
ChronOS (Synthes)
Conduit (DePuy)
Cellplex TCP (Wright Medical)
Various Theri__ names (Therics)
42. Bone Morphogenetic Proteins Produced by recombinant technology
Two most extensively studied and commercially available
BMP-2 (Infuse) Medtronics
BMP-7 (OP-1) Stryker Biotech Two bone morphogenetic proteins are commercially available. These are BMP-2,marketed by Medtronics, and BMP-7, more commonly known of osteogenic protein 1, produced by Stryker Biotech.
These products are produced by recombinant technology in which large quantities of the material are produced in cell culture.Two bone morphogenetic proteins are commercially available. These are BMP-2,marketed by Medtronics, and BMP-7, more commonly known of osteogenic protein 1, produced by Stryker Biotech.
These products are produced by recombinant technology in which large quantities of the material are produced in cell culture.
43. BMP-2 for Open Tibial Fractures Prospective, randomized study
450 patients BMPs have been studies in several human investigations including open fractures and nonunions.
BMP-2 was studied in a prospective, randomized study of 450 patients with open tibial shaft fractures treated with fracture debridement and an IM nail. At the time of definitive wound closure patients were randomized to one of three treatments
placebo
0.75 mg/ml BMP-2/ACS (lower BMP dose)
1.50 mg/ml BMP-2/ACS (higher BMP dose)
BMPs have been studies in several human investigations including open fractures and nonunions.
BMP-2 was studied in a prospective, randomized study of 450 patients with open tibial shaft fractures treated with fracture debridement and an IM nail. At the time of definitive wound closure patients were randomized to one of three treatments
placebo
0.75 mg/ml BMP-2/ACS (lower BMP dose)
1.50 mg/ml BMP-2/ACS (higher BMP dose)
44. 44% reduction in risk of nonunion/delayed union with high dose BMP-2
Significantly faster fracture healing
Significantly fewer
invasive interventions
hardware failures
infections
Results The primary outcome measure was the proportion of patients requiring secondary intervention because of delayed union or nonunion within twelve months postoperatively.
In the group treated with the higher dose BMP-2 there was a 44% reduction in risk of nonunion/delayed union
Significantly faster fracture healing
Significantly fewer invasive interventions
Significantly fewer hardware failures and fewer infections
The graph from their publication shows the placebo control groups in black representing the standard of care. The Gustilo IIIB's are on the left and the Gustilo I, II and IIIA's on the right. There is a statistically significant reduction in the number of secondary interventions in those fractures treated with the higher dose of BMP-2.
The primary outcome measure was the proportion of patients requiring secondary intervention because of delayed union or nonunion within twelve months postoperatively.
In the group treated with the higher dose BMP-2 there was a 44% reduction in risk of nonunion/delayed union
Significantly faster fracture healing
Significantly fewer invasive interventions
Significantly fewer hardware failures and fewer infections
The graph from their publication shows the placebo control groups in black representing the standard of care. The Gustilo IIIB's are on the left and the Gustilo I, II and IIIA's on the right. There is a statistically significant reduction in the number of secondary interventions in those fractures treated with the higher dose of BMP-2.
45. Indications for Bone Graft Provide mechanical support
Metaphyseal impaction
27 y.o male with lateral split/depression tibial plateau fracture. Note posterolateral depression.
46. Indications for Bone Graft Provide mechanical support
Metaphyseal impaction
ORIF with allograft cancellous bone chips to fill defect and support depressed area
Alternatively could use any osteoconductive substitute with similar compressive strength
47. Indications for Bone Graft Provide mechanical support
Metaphyseal impaction
4 months s/p surgery and the graft is well incorporated.
48. Indications for Bone Graft Provide mechanical support
Metaphyseal impaction
Replace bone
Cortical or segmental defect
29 y.o male with defect s/p IMN Type IIIB open tibia fracture. Gentamicin PMMA beads were used as spacers and removed.
49. Indications for Bone Graft Provide mechanical support
Metaphyseal impaction
Replace bone
Cortical or segmental defect
s/p bone grafting with iliac crest autograft.
50. Indications for Bone Graft Provide mechanical support
Metaphyseal impaction
Replace bone
Cortical or segmental defect
14 months after injury, the fracture is healed and the nail removed.
51. Indications for Bone Graft Provide mechanical support
Metaphyseal impaction
Replace bone
Cortical or segmental defect
Stimulate healing
Atrophic and Oligotrophic Nonunions
26 y.o. woman with established atrophic nonunion of the clavicle.
52. Indications for Bone Graft Provide mechanical support
Metaphyseal impaction
Replace bone
Cortical or segmental defect
Stimulate healing
Atrophic and Oligotrophic Nonunions
Plating with cancellous iliac crest autograft.
53. Indications for Bone Graft Provide mechanical support
Metaphyseal impaction
Replace bone
Cortical or segmental defect
Stimulate healing
Atrophic and Oligotrophic Nonunions
6 months after surgery, she is healed and asymptomatic.
54. Indications for Bone Graft Provide mechanical support
Metaphyseal impaction
Replace bone
Cortical or segmental defect
Stimulate healing
Nonunions
Arthrodesis
Failed subtalar arthrodesis
55. Indications for Bone Graft Provide mechanical support
Metaphyseal impaction
Replace bone
Cortical or segmental defect
Stimulate healing
Nonunions
Arthrodesis
Repeat fusion with autogenous iliac crest.
56. Indications for Bone Graft Provide mechanical support
Metaphyseal impaction
Replace bone
Cortical or segmental defect
Stimulate healing
Nonunions
Arthrodesis
6 months after surgery, fused successfully
57. Summary